Treatment Efficacy and Safety of Bortezomib Combined with Dexamethasone and Lenalidomide Chemotherapy Regimen for Multiple Myeloma  

作　　者：Changyong Yuan Na Cui Shumei Liu 

机构地区：[1]Department of Hematology,Dezhou Hospital,Qilu Hospital,Shandong University,Dezhou 253000,Shandong Province,China [2]School of Clinical Medicine,Shandong Second Medical University,Weifang 261000,Shandong Province,China

出　　处：《Journal of Clinical and Nursing Research》2024年第5期7-12,共6页临床护理研究（英文）

基　　金：Shandong Medical Association Clinical Research Specialization(YXH2022ZX03231)。

摘　　要：Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly,with 30 cases in each group.Bortezomib combined with dexamethasone was administered in the control group,and bortezomib combined with dexamethasone and lenalidomide was given to the observation group,and the treatment effect was analyzed.Results:After treatment,CD^(3+)and CD^(4+)of the observation group were higher than that of the control group,CD^(8+)was lower than that of the control group,and the total treatment efficiency was higher,which was statistically significant(P<0.05),and there was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe,thus it can be promoted in clinical practice.

关 键 词：Multiple myeloma BORTEZOMIB DEXAMETHASONE LENALIDOMIDE Efficacy Safety 

分 类 号：R73[医药卫生—肿瘤]